Intellia Therapeutics Balance Sheet
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Intellia Therapeutics financial position
At the end of fiscal 2025, Intellia Therapeutics reported total assets of $842.1 million, down 29.3% from a year earlier against total liabilities of $170.7 million. Shareholders' equity stood at $671.4 million, or 79.7% of assets. The company held $155.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 5.08, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Intellia Therapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 155.46M | 189.18M | 226.75M | 523.51M | 123.41M | 160.02M | 57.23M | 58.86M | 340.68M | 273.06M |
| Short-Term Investments | 294.42M | 412.33M | 685.48M | 669.12M | 625.28M | 437.35M | 222.50M | 255.20M | — | — |
| Receivables | 9.47M | 8.52M | 36.46M | 3.77M | 2.03M | 2.13M | 4.62M | 7.55M | 10.47M | 6.45M |
| Total Current Assets | 527.71M | 639.86M | 998.33M | 1.22B | 769.30M | 616.52M | 289.48M | 324.98M | 354.83M | 281.31M |
| Property, Plant & Equipment | 17.67M | 27.38M | 32.76M | 27.92M | 20.97M | 15.94M | 18.00M | 17.06M | 15.27M | 10.63M |
| Long-Term Investments | 155.25M | 260.21M | 99.86M | 69.34M | 337.36M | 0 | 4.75M | — | — | — |
| Total Assets | 842.13M | 1.19B | 1.30B | 1.52B | 1.29B | 676.32M | 334.28M | 347.31M | 376.24M | 298.97M |
| Accounts Payable | 20.25M | 14.59M | 7.45M | 5.15M | 9.65M | 10.46M | 3.94M | 2.71M | 2.17M | 4.65M |
| Total Current Liabilities | 103.88M | 110.85M | 115.21M | 126.55M | 125.83M | 64.25M | 35.63M | 40.57M | 31.36M | 30.73M |
| Total Liabilities | 170.73M | 319.06M | 250.81M | 284.53M | 254.22M | 149.25M | 64.40M | 69.39M | 75.64M | 89.13M |
| Shareholders' Equity | 671.39M | 871.96M | 1.05B | 1.24B | 1.04B | 527.07M | 269.88M | 277.92M | 300.60M | 209.84M |
| Retained Earnings | -2.59B | -2.18B | -1.66B | -1.18B | -703.00M | -435.11M | -300.88M | -201.03M | -121.11M | -53.57M |
| Net Cash (Debt) | 449.88M | 601.51M | 912.22M | 1.19B | 748.69M | 597.37M | 279.73M | 314.06M | 340.68M | 273.06M |
| Shares Outstanding | 116.32M | 102.03M | 93.00M | 87.10M | 74.49M | 66.23M | 50.20M | 45.22M | 42.38M | 36.02M |
This table shows 10 annual periods of Intellia Therapeutics's balance sheet, from FY 2025 back to FY 2016, across 14 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow NTLA's reporting calendar. What is a balance sheet?